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in high-risk groups. The aim of this study was to assess the cost-effectiveness (CE)
of voriconazol, amphotericin B and caspofungin as first line treatments for IA adult
inmunosupressed patients in Dominican Republic, from the public healthcare
perspective. METHODS: A decision-tree model was used to compare costs and
effectiveness of amphotericin B (basecase) IV (15mg/kg/day), caspofungin IV (Initial
dosage 70mg/day, maintenance dosage 50mg/day) and voriconazole IV (12mg/kg/
day). Effectivenessmeasures were: clinical success rates, mortality rates, intensive
care unit (ICU) length of stay (LOS) and hospital ward LOS. Effectiveness and epi-
demiologic data, was collected from published literature. Local public costs (2011
US$) were obtained from Dominican Republic=s Social Security official databases.
The model used a 12-week time horizon and only direct medical costs were con-
sidered. Monte Carlo probabilistic sensitivity analysis (PSA) was constructed.
RESULTS: Voriconazole resulted as the least expensive and most effective option
for IA patients. Clinical success rate was higher with voriconazole (56.6%) com-
pared with amphotericin B (36.4%) and caspofungin (34.2%). Mortality rates were:
34.1% with voriconazole, 50.9% with amphotericin B and 44.7% with caspofungin.
Considering ICU LOS against voriconazole, LOS resulted 2.22 and 2.35 days higher
with amphotericin B and caspofungin, respectively. Hospital ward LOS was also
higher with amphotericine B (16.4 days) and caspofungina (16.5 days) against vori-
conazole (15.4 days). Overall medical costs were: US$26,078.22 with voriconazole,
US$29,240.17 with amphotericin B and US$33,514.01 with caspofungin. Cost effec-
tiveness analyses showed voriconazole as the cost-saving strategy. PSA outcomes
support the robustness of these findings. CONCLUSIONS: This is the first CE study
for IA developed in Dominican Republic within the public sector. Voriconazole
would generate savings over US$3000 per patient in the Dominican’s clinical public
context.
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OBJECTIVES: Ventilator-associated pneumonia (VAP) is associated with increasing
intensive care unit (ICU) admissions, morbidity and length of stay (LOS) as it’s one
of the most common nosocomial infections in the ICU; raising overall costs. Liter-
ature suggests costs could be significantly reduced by using the most efficient
empiric therapy. The aim of this study was to assess the cost-effectiveness (CE) of
linezolid against generic vancomycin as an empiric therapy for adult VAP patients,
from the private health care perspective.METHODS: A cohort of patients with VAP
in the ICU was simulated using a decision-tree model to compare costs and effec-
tiveness of linezolid (600 mg/12 hours) and vancomycin (15 mg/kg/12 hours) (base-
case) over 10-28 days. Effectiveness measures were: clinical success rates, mortal-
ity rates, and hospital and ICU LOS. The model used a 12-week time horizon and
only direct medical costs were considered (inpatient costs, medication expenses,
adverse events costs, hematologic and gastrointestinal tests) Effectiveness and
epidemiologic data were retrieved from published literature. Local costs (2011 US$)
were gathered from Dominican Republic=s capital’s private hospital databases.
Monte Carlo probabilistic sensitivity analysis (PSA) was constructed. RESULTS:
Linezolid resulted as the most effective and less expensive option for VAP adult
patients. Clinical success rate was higher with linezolid (64%) against vancomicyn
(59.5%). Mean expected ICU LOS was 17.4 days for linezolid and 21.26 days for
vancomycin; mean expected hospital LOS was 8.44 days versus 9.43 days, respec-
tively. Mortality rate was found lower in the linezolid arm (10.13%) in comparison
to vancomycin (15.74%). Overall costs per patient were $53,922.91 with linezolid
and $67,437.44 with vancomycin. In the CE incremental analysis, linezolid ap-
peared as the cost-saving option. PSA outcomes support the robustness of these
findings. CONCLUSIONS: Linezolid resulted as the cost-saving therapy for treating
VAP adult patients in ICU in the Dominican private clinical context.
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OBJECTIVES: Investigate cost-effectiveness of sildenafil versus bosentan for treat-
ment of pulmonary arterial hypertension (PAH) patientswithWHO functional class
(FC) II and III disease, in five European countries. METHODS: A decision-analysis
model followed patients over 48 weeks through four health states: FC II, III, IV, and
death. Model outcomes were: total treatment costs, quality-adjusted life-years
gained, and incremental cost-effectiveness ratio Baseline demographics, transi-
tion probabilities and PAH-related mortality were based on data from 12 weeks of
therapy in the SUPER-1 (sildenafil arms) and STRIDE-2 trials (bosentan arm). Utility
values (SF36, EQ5D) for each health state were obtained from published sources
and assumed to be equal between sildenafil and bosentan. Separate models were
built for France, Italy, Germany, Spain and United Kingdom. Health resource use
was estimated by interviewing local clinicians experienced in PAH. A base case
analysis was conducted from the payer’s perspective which considered the direct
costs of treatment. Unit costswere based on local tariffs and published data. To test
the robustness of the results, univariate and probabilistic sensitivity analyses (PSA)
were performed. RESULTS: Total treatment costs were significantly lower for silde-
nafil versus bosentan (cost differences range: €17.8k to €37.9k). Sildenafil domi-
nated bosentan in each country. The key factor for this benefit was the lower
acquisition cost of sildenafil. PSA indicated that the results were robust (cost dif-
ference: €17.6k to €36.7, 95% CI). Sensitivity analyses showed that the costs of
treatment with sildenafil remained lower compared to bosentan when FC III pa-
tients received combination therapy (cost differences range from €11.95k to €25.8k).
CONCLUSIONS: In the countries analyzed, sildenafil is a cost-effective treatment
for patients with PAH. Limitations include lack of long-term data, use of open-label
trial data (STRIDE-2), and that current practice includes therapeutic options such as
combination therapy for which prospective clinical trial data are currently lacking.
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BACKGROUND: Omalizumab is a monoclonal antibody that inhibits the activity of
the immunoglobulin E. Omalizumab has been shown to significantly reduce
asthma exacerbations and health resources utilization compared with standard
therapy. A cost-utility analysis is justified to assess the economic impact of omali-
zumab adoption by the Colombian health care system. OBJECTIVES: To estimate
the cost-utility of omalizumab added to standard therapy comparedwith standard
therapy alone in patients over 12 years old with severe allergic asthma from the
perspective of the Colombian health care system. METHODS: We performed a
cost-utility analysis comparing direct health care costs, QALYs and exacerbations
in both treatment arms. We used a Markov model to project costs and exacerba-
tions over 20 years. Cost information was obtained from local hospital records and
medication average annual consumption from a logistic operator. Exacerbations
and QALYs were projected based on the scientific literature. We implemented a
Monte Carlo probabilistic sensitivity analysis. Annual discount rate was 3%. Ex-
change rate used was 1.932 pesos per dollar (Nov 2011) RESULTS: Total cost [US $]
of omalizumab added to standard therapy versus standard therapy alone was
$90.686 IC95% ( 647,4) and $ 77.777 IC95% ( 648,4), respectively. QALYs gained
was 12.07 ( 0.0032) and 11.45 ( 0.0044) for both arms. Exacerbations with omali-
zumab and standard therapy were 5.7 IC95% ( 0.015) and 8.7 IC95% ( 0.020),
respectively. Incremental cost per QALY gained was $12.361 ( 167). Incremental
cost per exacerbation avoided was $4.367 IC95% ( 55,6). CONCLUSIONS: Accord-
ing to these assumptions the incremental cost per QALY gained and incremental
cost per avoided exacerbation is reasonable. But without a clear threshold in Co-
lombia, decision is up to the evaluator.
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OBJECTIVES: This study aimed to explore the impact of smoking on productivity in
ChronicObstructive PulmonaryDisease (COPD).METHODS:Data from theNational
Health and Wellness Survey (NHWS) were used for this study. Respondents aged
40 reporting diagnoseswith COPD, chronic bronchitis, or emphysema in theUS in
2009 or 2010 were included, using 2010 data for individuals completing the survey
in both years. The smoking group included subjects diagnosed with COPD who
reported currently smoking (n1685). The former smoker group consisted of those
diagnosed with COPD who reported not smoking in the last 11 years (n1932).
The Work Productivity and Activity Impairment scale (WPAI) assessed productiv-
ity, including absenteeism, presenteeism, and overall work and non-work activity
impairment. Multivariate generalized linear models were used to predict produc-
tivity impairment, with a negative binomial distribution and a log-link function.
Covariates included age, sex, race, insurance status, marital status, income, BMI,
alcohol use, exercise, and asthma diagnosis. Indirect costs were calculated using
the U.S. Department of Labor’s 2009 Bureau of Labor Statistics average wages,
adjusted for gender and age. These were multiplied by productivity impairment
and then annualized to project yearly costs associated with lost productivity.
RESULTS: Multivariable results for productivity data estimated the following dif-
ferences between current smokers with COPD and former smokers with COPD:
absenteeism (3% vs. 1%, p.355), presenteeism (23% vs. 18%, p0.010), overall work
impairment (25% vs. 21%, p0.043) and activity impairment (52% vs. 49%, p0.004).
Calculated mean indirect costs were estimated to be $10,905 versus $7,819
(p0.002), or incremental mean indirect costs of $3,096 per year for current
smokers.CONCLUSIONS:Comparedwith former smokers quitting 10 years prior,
COPD sufferers currently smoking have similar absenteeism, greater presentee-
ism, and mildly impaired overall work and activity impairment. Estimated incre-
mental costs of productivity decreases are $3096 per year for current smokers with
COPD.
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OBJECTIVES: To assess health care resource utilization and related costs among
managed care patients treated for chronic bronchitis (CB).METHODS: A retrospec-
tive analysis of the HealthCore Integrated Research Database (HIRD) was con-
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